WT1 and hematopoietic and lymphoid cell neoplasm: This is further evidenced by superior activation of both the WT1-specific CD8+ T-cell clone used in this paper and antigen-specific CD8+ T-cells from hematological cancer patients [17] after stimulation with IL-15-transpresenting DC.